key: cord-0758244-7lrnin6l
authors: Zhang, Jishou; Wang, Menglong; Ding, Wen; Wan, Jun
title: The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
date: 2020-07-24
journal: Life Sci
DOI: 10.1016/j.lfs.2020.118142
sha: 4e6fba9de4ef4267794ec1d3e21eb4b364ffb93f
doc_id: 758244
cord_uid: 7lrnin6l

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently defined as the worst pandemic disease. SARS-CoV-2 infects human cells via the binding of its S protein to the receptor angiotensin-converting enzyme (ACE2). The use of ACEIs/ARBs (RAAS inhibitors) regulates the renin-angiotensin-aldosterone system (RAAS) and may increase ACE2 expression. Considering the large use of ACEIs/ARBs in hypertensive patients, some professional groups are concerned about whether the use of RAAS inhibitors affects the risk of SARS-CoV-2 infection or the risk of severe illness and mortality in COVID-19 patients. In this review, we summarize preclinical and clinical studies to investigate whether the use of ACEIs/ARBs increases ACE2 expression in animals or patients. We also analyzed whether the use of these drugs affects the risk of SARS-CoV-2 infection, severe illness or mortality based on recent studies. Finally, the review suggests that current evidence does not support the concerns.

J o u r n a l P r e -p r o o f 6 storm", which, in turn, is responsible for multiple organ injury [40] [41] [42] . In addition to expression in the respiratory system, co-expression of the two proteins has also been documented in the gastrointestinal system, cardiomyocytes, and some other tissues [38] . Another study reported that ACE2 expression was highest in the small intestine, testes, kidneys, heart, thyroid, and adipose tissue and that there was medium expression in the lungs, colon, liver, bladder, and adrenal gland [43] . The widespread expression of ACE2 suggests that the virus may invade multiple organs and cause organ damage. The brief showed in Figure 1 .

In addition, previous studies have supported that SARS-CoV infection reduces the expression of surface ACE2 in mice, which is associated with the worsening of acute lung injury [44] . Since SARS-CoV-2 and SARS-CoV share similar spike proteins, receptors and pathological processes, we speculate that SARS-CoV-2 infection may also decrease ACE2 expression. The decreased ACE2 expression in membrane could inhibit the production of Ang 1-7 and Ang 1-9 [25] . Since the metabolite Ang 1-7, as the end-point of ACE2/Ang 1-7/MasR axis, plays a critical role in maintaining the balance of RAAS [45] . The inhibition of ACE2/Ang 1-7/MasR will be associated with the enhanced activation of Ang II/AT1R, which furtherly promotes the internalization of ACE2 [24] and results in a vicious circle of the imbalance. In brief, SARS-CoV-2 infection may induce and aggravate the imbalance between ACE2/Ang 1-7/MasR and Ang II/AT1R, which promotes the aggravation of viral pneumonia or lung injury. The brief showed in Figure 1 .

J o u r n a l P r e -p r o o f 7 related studies [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] are listed in Table 1 . Kidoguchi et al. [46] analyzed the expression of ACE2 in adenine-induced chronic renal failure model mice, and the results suggested that azilsartan did not increase ACE2 expression in the kidney compared to the control group. However, de Jong MA et al. [49] revealed that losartan increased ACE2 mRNA by approximately 2-fold in contralateral (unaffected) kidneys in a unilateral ureteral obstruction (UUO) model. Another diabetic nephropathy model reported that the dose (1 mg/kg/d) of candesartan increased ACE2 expression and activity in the kidney cortex from diabetic mice, and different doses of candesartan also increased ACE2 activity by 25%-50% in the plasma of diabetic mice [51] .

Nevertheless, candesartan did not increase ACE2 activity in control mice. In the heart, inserting the human renin and angiotensinogen genes into mice decreased ACE2 expression in cardiac tissue, but azilsartan, not olmesartan, recovered this change [52] .

Another ARB, telmisartan, was reported to elevate the expression of cardiac ACE2 in a chronic intermittent hypoxia model [48] . However, Burchill et al. suggested that neither ramipril treatment alone nor in combination with valsartan augmented cardiac ACE2 expression in myocardial infarction mice [53] . Other studies on the effect of RAAS blockers on ACE2 expression in several organs, such as the heart, kidney, brain, intestine and thoracic aorta, are shown in table 1. According to these preclinical studies, there is no consistent evidence that the use of RAAS inhibitors leads to an increase in ACE2 expression during the pathologic course of the disease (Figure 2 ).

The phenomenon may depend on different disease models, drugs, or doses. Although the expression levels of ACE2 are increased, the changes are also limited. The limited increase in ACE2 levels may not be associated with the increased risk of or not have an effect on the progression of COVID-19. Further observations need to be performed in clinical studies.

J o u r n a l P r e -p r o o f 8 activity was increased in male (10%) and female (20%) diabetes patients who were on ACEI treatment [61] . Additionally, Vuille-dit-Bille et al. [62] concluded that ACEIs but not ARBs increased intestinal mRNA levels of ACE2 by 1-fold in patients. In 2020, SARS-CoV-2 is rapidly spreading around the world, and the concern that RAAS inhibitor use may affect its transmission and pathogenic ability has attracted the attention [65] . Recently, 2 studies on the effects of RAAS inhibitors on ACE2 expression were performed. In one study, plasma ACE2 concentrations in 1485 men and 537 women with heart failure (index cohort) were measured [63] . The results were validated in 1123 men and 575 women (validation cohort). In the index cohort, ACEI or ARB use was not an independent predictor of plasma ACE2 levels [63] . In the validation cohort, both ACEIs (estimate = -0.17, P = 0.002) and ARBs (estimate = -0.15, P = 0.03) were independent predictors of lower plasma ACE2 [63] . Milne et al. [64] reported another clinical study that included 1051 lung tissue samples from the Human Lung Tissue Expression Quantitative Trait Loci Study (Lung eQTL Study) and investigated the gene expression of ACE2 and two relative host cell proteases (TMPRSS2 and ADAM17) that were used as cofactors for virus entry. The results showed that ACEI use was associated with significantly lower expression of ACE2 and TMPRSS2 but was not associated with ADAM17 expression [64] . ARB use was not associated with changed expression levels of these three genes [64] . According to these clinical studies, there is no strong evidence to support the idea that the use of RAAS inhibitors increases ACE2 expression in patients ( Figure 2) . Therefore, the hypothesis that RAAS inhibitor use may increase the risk of COVID-19 has hardly been demonstrated.

To analyze the interaction between RAAS inhibitors and SARS-CoV-2 infection, we need direct clinical study data. After searching the PubMed databases, we recruited one population-based case-control study [66] and three other retrospective studies [67] [68] [69] , all of which are shown in Table 3 .

Mancia et al. [66] performed a case-control study that involved patients with Journal Pre-proof J o u r n a l P r e -p r o o f 9 confirmed COVID-19 in the Lombardy region of Italy. The study included 6272 COVID-19 patients and 30759 controls who were matched based on age, sex, and municipality of residence. In a conditional logistic regression multivariate analysis, neither ACEIs nor ARBs use were associated with the risk of SARS-CoV-2 infection [66] . Reynolds et al. [68] reported a multicenter study involving 12,594 patients. Among these, 5894 (46.8%) were diagnosed with COVID-19, and 1002 had severe illness. The results indicated that there was no association between any single medication class (e.g., ACEIs, ARBs, or other antihypertensive drugs) and an increased likelihood of SARS-CoV-2 infection [68] . In a retrospective cohort study [69] from Ohio and Florida, USA, a total of 18472 patients were tested for COVID-19. Of these, 2285 (12.4%) were taking ACEIs/ARBs, and 1735 (9.4%) had a positive COVID-19 test result. The overlap propensity score weighting showed that there was no significant association of ACEI and/or ARB use with COVID-19 test positivity (OR, 0.97; 95% CI, 0.81-1.15) [69] . In addition, Dauchet et al. [67] concluded that the standardized prevalence ratio (SPR) of consumption of ACEI and ARB drugs in COVID-19 patients was similar to the regular consumption of this drug in the reference samples.

None of the five studies provide evidence to support the hypothesis that ACEI or ARB use is associated with the risk of SARS-CoV-2 infection ( Figure 2 ). We suggest that hypertensive patients and other patients taking RAAS inhibitors (e.g., those with chronic heart failure, chronic renal failure and diabetes) [19, 70] should not discontinue the use of RAAS inhibitors.

To investigate the interaction of RAAS inhibitors with the severe illness or mortality of COVID-19, we searched the PubMed database. A total of eleven original retrospective clinical studies [66, 68, [71] [72] [73] [74] [75] [76] [77] [78] [79] were conducted and are shown in Table 4 .

In addition, a prospective study based on an ongoing randomized clinical trial (NCT03201185) [80] randomly allocating ramipril or control among patients with successful transcatheter aortic valve replacement was collected.

J o u r n a l P r e -p r o o f 10 First, we analyzed the current or previous use of RAAS inhibitors. Mancia et al. [66] recruited 6272 patients with COVID-19 in Italy and concluded that there was no evidence that the use of ACEIs or ARBs increased the risk of COVID-19 severe or fatal illness. Reynolds et al. [68] reported 5894 COVID-19 patients in New York and suggested that neither ACEIs nor ARBs were associated with a significant increase in the risk of severe illness. In both of the studies described above, the medication data were extracted from medical histories. Abajo et al. [73] collected data for 1139 patients with positive COVID-19 test and 11390 population controls in Spain and defined exposure to the drugs (ACEIs/ARBs) as current use. They concluded that ACEIs/ARBs did not affect the risk of COVID-19 requiring admission to hospitals, including these fatal cases and critical cases (admitted to the ICU), which indicated that these drugs should not be discontinued or replaced. In another study from South Korea [74] , the author identified all RAAS inhibitors that were prescribed within 1

year before the index date. They also concluded that prior use of RAAS inhibitors was not independently associated with mortality among COVID-19 patients. A similar conclusion was also supported by several other studies with small sample sizes from China [72, [76] [77] [78] .

Second, we analyzed the association between the continued use of RAAS inhibitors during hospitalization or observation and severe or fatal illness. P Zhang et al. [71] reported a multicenter retrospective study, and 1128 adult patients with hypertension who were diagnosed with COVID-19 were enrolled. Patients with hypertension were classified as the ACEI/ARB group (n=188) or non-ACEI/ARB group (n=940) according to whether they received ACEI/ARB treatment during hospitalization. The results found that the ACEI/ARB group had a lower unadjusted mortality than the non-ACEI/ARB group (3.7% vs. 9.8%; P = 0.01). After adjusting for age, sex, comorbidities and in-hospital medications, the observed risk for all-cause in-hospital mortality was still lower in the ACEI/ARB group than in the non-ACEI/ARB group (adjusted hazard ratio, 0.42; 95% CI, 0.19-0.92; P =0.03). In a propensity score-matched analysis followed by balancing relative variables, similar Journal Pre-proof J o u r n a l P r e -p r o o f 11 results were observed (adjusted hazard ratio, 0.37; 95% CI, 0.15-0.89; P = 0.03). In a further subgroup propensity score-matched analysis, the risk of all-cause mortality was also lower in the ACEI/ARB group than in the group using other antihypertensive drugs (adjusted hazard ratio, 0.30; 95% CI, 0.12-0.70; P = 0.01). The study suggested that the inpatient use of RAAS inhibitors may decrease the risk of all-cause mortality in patients with hypertension and COVID-19. J Li et al. [63] conducted another single-center retrospective study in which 362 COVID-19 patients with hypertension were enrolled, including 115 patients (31.8%) taking ACEI/ARBs at admission with continued use during hospitalization. The results concluded that there were no differences in the percentage of patients taking ACEIs/ARBs between those with severe and nonsevere infections or between nonsurvivors and survivors. In addition, a small retrospective study from China concluded that there were no obvious differences in clinical characteristics, including clinical severity, clinical course and in-hospital mortality, between the RAAS inhibitor group and the non-RAAS inhibitor group [79] . Although all three studies were retrospective and the interpretation of the conclusion was interfered by some underlying confounders, it is impossible to support the hypothesis that inpatient use of RAAS inhibitors is associated with an increased risk for severe illness or mortality.

To evaluate if RAAS inhibitors affect the risk for COVID-19, a prospective study has reached a preliminary conclusion [80] . The prospective study was based on an ongoing randomized control study, which allocated ramipril or control among patients with successful transcatheter aortic valve replacement. The study enrolled 102 patients including 50 ramipril and 52 controls, and these patients took the medicine for at least a month. The results found that ramipril was not associated with the incidence or severity of COVID-19 in the old patients with cardiovascular disease. ACEI use was associated with significantly lower ACE2 and TMPRSS2 expression, but was not associated with ADAM17 expression. ARBs were not associated with altered expression of these three genes. 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Guide to Understanding the 2019 Novel Coronavirus

Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

ACE-2/ANG1-7 ameliorates ER stress-induced apoptosis in seawater aspiration-induced acute lung injury

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis

The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan

Vascular Type 1A Angiotensin II Receptors Control BP by Regulating Renal Blood Flow and Urinary Sodium Excretion

Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade

Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism

Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling

Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes

Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1-7) Mas receptor knockout mice

Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Ang II (Angiotensin II) Conversion to

-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent

Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers

Structure, Function, and Evolution of Coronavirus Spike Proteins

Coronaviruses post-SARS: update on replication and pathogenesis

Cell entry mechanisms of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin

Azilsartan causes natriuresis due to its sympatholytic action in kidney disease

Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats

Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity

Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis

Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice

Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis

Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan

Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions

overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition

Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats

Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats

Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme

Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy

Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications

Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments. The ACER-COVID study

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Association of Use of

Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study

COVID-19 with Different Severity: A Multi-center Study of Clinical Features

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Ramipril in High Risk Patients with COVID-19

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

Estimation of RAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis

Decreased Mortality of COVID-19 with

Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis

Angiotensin-(1-7) protects from experimental acute lung injury

Therapeutic time window for angiotensin-(1-7) in acute lung injury

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism

National Library of Medicine. Coronavirus (COVID-19) ACEi/ARB

ClinicalTrials.gov Identifier: NCT04330300

Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)

NCT04355429?term=NCT04355429&draw =2&rank=1 on

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19